ICARS provides a unique value proposition – a funded partnership, collaborating with low- and middle-income countries to co-develop evidence-based, context specific, cost-effective and sustainable solutions to mitigate AMR, advancing each country’s individual National Action Plan.

At ICARS, our mission is to partner with Low- and Middle-income countries (LMICs) in their efforts to reduce drug-resistant infections. We do this by co-developing tailored solutions with LMIC governments and researchers, who then implement them on the ground using ICARS funding and expertise, building on AMR National Action Plans.